Melanoma patients who responded to the combination therapy of anti-LAG-3 and anti-PD-1 were found to have higher NK cell levels in the tumours and greater transcriptional changes associated with IFN-γ responses, cytotoxicity, and degranulation [20]. The gene discussed is PDCD1; the disease is melanoma.